ERAS

Erasca Inc

14.98

Oct 29 • 3:59 PM ET -0.14 (-0.93%)

14.98

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: RVMD BBOT VSTM TNGX IMRX IDYA RLAY COGT AMGN BMY

| Held by: VTI XBI IWM VB VXF VBR IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT
Market Cap	5.24B
Enterprise Value	5.02B
Income	-287.22M
Sales	0.00M
Book/sh	1.16
Cash/sh	0.77
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	103
IPO	Jul 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	12.94
P/C	19.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.29
Current Ratio	8.29
Debt/Eq	0.12
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-0.95
EPS next Y	-0.62
EPS next Q	-0.13
EPS this Y	-121.20%
EPS next Y	36.24%
EPS next 5Y	-20.83%
EPS past 3/5Y	39.56% 12.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	-110.63%
Sales Y/Y TTM	-
EPS Q/Q	-18.39%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-25.67% -

Insider Own	29.33%
Insider Trans	0.00%
Inst Own	61.84%
Inst Trans	3.06%
ROA	-65.25%
ROE	-78.25%
ROIC	-71.60%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.89%
SMA50	-3.59%
SMA200	0.05%
Trades

Shs Outstand	312.56M
Shs Float	247.18M
Short Float	14.95%
Short Ratio	8.40
Short Interest	36.96M
52W High	24.28 -38.30%
52W Low	2.11 611.64%
Volatility	5.78% 6.85%
ATR (14)	0.97
RSI (14)	50.58
Beta	0.69
Rel Volume	0.52
Avg Volume	4.40M
Volume	2,280,617

Perf Week	6.70%
Perf Month	2.18%
Perf Quarter	-17.47%
Perf Half Y	40.66%
Perf YTD	302.69%
Perf Year	534.75%
Perf 3Y	652.76%
Perf 5Y	-24.27%
Perf 10Y	-
Recom	1.40
Target Price	23.70
Prev Close	15.12
Price	14.98
Change %	-0.93%

Consensus

Strong Buy

Avg. Price Target

$23.70

Implied Upside

+58.2%

Analysts10incl. previous ratings

Rating Distribution8 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 04, 2026	Upgrade	BBofA Securities	Underperform → Neutral	$16	+6.8%
Jan 27, 2026	Resumed	MMizuho	Outperform	$16	+6.8%
Jan 07, 2026	Initiated	PPiper Sandler	Overweight	$5	-66.6%
Oct 16, 2025	Initiated	SStifel	Buy	$4	-73.3%
Sep 03, 2025	Downgrade	BBofA Securities	Buy → Underperform
Aug 18, 2025	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$2	-86.6%
Mar 26, 2025	Initiated	RRaymond James	Outperform	$5	-66.6%
Nov 18, 2024	Initiated	JJefferies	Buy	$6	-59.9%
Mar 11, 2024	Initiated	CCapitalOne	Overweight	$8	-46.6%
Jan 05, 2024	Downgrade	BBofA Securities	Buy → Neutral	$11 → $6	-59.9%
Oct 11, 2023	Initiated	HH.C. Wainwright	Buy	$10	-33.2%
Mar 30, 2023	Initiated	MMizuho	Buy	$9	-39.9%
Feb 24, 2023	Initiated	GGoldman	Buy	$10	-33.2%
Feb 03, 2023	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$15	+0.1%

Sep-10-26 08:00AM	Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-08-26 07:00AM	Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-24-26 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma (GlobeNewswire)
Aug-11-26 04:01PM	Erasca Reports Second Quarter 2026 Business Updates and Financial Results (GlobeNewswire)
Aug-10-26 04:01PM	Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
08:00AM	Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D (GlobeNewswire)
Aug-05-26 01:45PM	Kaplan Fox Encourages Erasca, Inc. (ERAS) Investors with Losses to Contact the Firm Before August 10, 2026 (Newsfile)
Jul-27-26 03:45PM	Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026 (Newsfile)
02:50PM	ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
04:41AM	Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS (PR Newswire)
Jul-20-26 11:30AM	Kaplan Fox Encourages Investors of Erasca, Inc. (ERAS) Who Suffered Losses to Contact the Firm Before August 10, 2026 (Newsfile)
Jul-15-26 04:01PM	Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +9.03% -10.54%
Jul-13-26 11:10PM	Erasca Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +8.94%
04:19PM	Erasca Announces Proposed Public Offering of $500 Million of Common Stock (GlobeNewswire)
04:01PM	Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors (GlobeNewswire)
04:58AM	Loading…
Jul-07-26 04:58AM	Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS (PR Newswire)
Jul-02-26 05:47PM	ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
08:20AM	Robinhood and 4 More Stocks That Were Just Added to This Firm's 'Top Picks' List (Barrons.com)
Jun-22-26 04:30AM	Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS (PR Newswire) +10.31%
Jun-04-26 03:30PM	Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset (PR Newswire)
May-28-26 09:00AM	Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset (PR Newswire)
May-27-26 08:00AM	Erasca to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.43%
May-21-26 09:00AM	Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset (PR Newswire)
May-11-26 04:01PM	Erasca Reports First Quarter 2026 Business Updates and Financial Results (GlobeNewswire)
07:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab) (GlobeNewswire)
May-06-26 08:00AM	Erasca to Present at the Bank of America Securities Health Care Conference (GlobeNewswire) +9.11%
Apr-30-26 08:03AM	Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results (Investor's Business Daily) +16.90%
Apr-29-26 03:07PM	Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges (GuruFocus.com) -7.98%
09:10AM	Erasca stock sinks 50% after patient death in drug trial (Quartz)
09:10AM	Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug (Investor's Business Daily)
09:10AM	Loading…
09:10AM	Erasca stock sinks almost 50% after patient death in cancer drug trial (Quartz)
Apr-28-26 03:58PM	Erasca Shares Crater After Cancer Trial Update Reveals Patient Death (The Wall Street Journal) -48.30%
12:29PM	Erasca Stock Sinks 50% in Race for 'Miracle' Cancer Drug. What's Behind the Historic Sell-Off. (Barrons.com)
10:30AM	BC-Most Active Stocks (Associated Press)
09:33AM	Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer (Investor's Business Daily)
05:57AM	FDA claims Amgen drug data were manipulated; Erasca slides despite home run results (BioPharma Dive)
Apr-27-26 04:01PM	Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors (GlobeNewswire) -10.89%
08:30AM	Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 (GlobeNewswire)
Mar-12-26 04:01PM	Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results (GlobeNewswire) -5.48% -7.03%
Mar-10-26 08:00AM	Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau (GlobeNewswire)
Mar-09-26 11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.)
Mar-06-26 09:45AM	TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS (Zacks)
Mar-05-26 04:10PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
07:01AM	Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat (GlobeNewswire)
Feb-28-26 03:15PM	Erasca, Inc. (ERAS): A Bull Case Theory (Insider Monkey)
Feb-27-26 08:08PM	Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 (MarketBeat) +6.37%
Feb-24-26 08:00AM	Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 (GlobeNewswire)
Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-05-26 08:00AM	Erasca to Present at Upcoming Conferences in February (GlobeNewswire) +5.69%
Feb-02-26 12:45PM	Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? (Barchart)
04:16AM	Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT (Insider Monkey)
Jan-30-26 09:48AM	Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models (Insider Monkey)
Jan-26-26 07:52AM	Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? (Benzinga)
Jan-23-26 04:01PM	Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-21-26 08:54PM	Erasca Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jan-20-26 04:01PM	Erasca Announces Proposed Public Offering of $150 Million of Common Stock (GlobeNewswire)
Jan-19-26 09:12PM	Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade (Insider Monkey)
Jan-16-26 11:33AM	Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike (Insider Monkey)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-15-26 04:34PM	These charts show the stock market giving investors a lot to like - for now - as the S&P 500 nears 7,000 (MarketWatch) +15.04%
04:12PM	David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 (Benzinga)
05:09AM	Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike (Insider Monkey)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) +10.73%
07:08AM	Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% (Insider Monkey)
Jan-12-26 08:00AM	Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones (GlobeNewswire) -7.84%
Jan-08-26 01:21PM	What's Going With Cancer Biotech Erasca Stock On Thursday? (Benzinga) +12.38%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +42.42%
Jan-06-26 08:00AM	Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Nov-29-25 01:26AM	Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results (Insider Monkey)
Nov-25-25 09:08AM	Erasca to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +6.23%
Nov-12-25 04:01PM	Erasca Reports Third Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +12.29%
Nov-06-25 08:00AM	Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 (GlobeNewswire)
Nov-04-25 08:00AM	Erasca to Present at Upcoming Conferences in November (GlobeNewswire)
Oct-27-25 01:09PM	Can Centene's Q3 Earnings Escape Industry's Cost Headwinds? (Zacks)
Oct-23-25 12:42PM	Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings? (Zacks)
Oct-21-25 12:13PM	Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here (Zacks)
Sep-02-25 08:00AM	Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-25 04:01PM	Erasca Reports Second Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +5.41%
Jul-31-25 11:40PM	Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors (Insider Monkey) -8.71%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
Jun-02-25 08:00AM	Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 (GlobeNewswire)
May-29-25 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire) +31.82%
May-13-25 04:05PM	Erasca Reports First Quarter 2025 Business Updates and Financial Results (GlobeNewswire)
08:00AM	Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway (GlobeNewswire)
May-07-25 08:00AM	Erasca to Present at the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-25 04:05PM	Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting (GlobeNewswire)
Apr-25-25 11:33AM	Erasca, Inc.: Carving A Different Niche In RAS Signaling (Seeking Alpha)
Apr-16-25 10:16AM	Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-25-25 04:31PM	Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-20-25 04:01PM	Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results (GlobeNewswire)
Jan-31-25 08:00AM	Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-21-25 09:35AM	Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-20-25 09:35AM	Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround (Zacks)
Jan-17-25 09:35AM	Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-16-25 09:35AM	Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-07-25 08:00AM	Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Nov-15-24 09:55AM	Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erasca Foundation	Foundation	Oct 15 '26	Proposed Sale	14.68	8,333	122,353		Oct 15 12:18 PM
Erasca Foundation	Foundation	Sep 15 '26	Proposed Sale	15.97	8,333	133,094		Sep 15 04:46 PM
Erasca Foundation	Foundation	Aug 17 '26	Proposed Sale	18.29	8,333	152,419		Aug 17 02:13 PM
Erasca Foundation	Foundation	Jul 21 '26	Proposed Sale	18.92	8,333	157,638		Jul 21 04:05 PM
Erasca Foundation	Foundation	Jun 15 '26	Proposed Sale	14.10	8,333	117,477		Jun 15 05:52 PM
Erasca Foundation	Foundation	May 15 '26	Proposed Sale	10.14	8,333	84,528		May 15 04:46 PM
Erasca Foundation	Foundation	Apr 15 '26	Proposed Sale	18.10	8,333	150,843		Apr 15 05:06 PM
Garner Ebun	Chief Legal Officer	Apr 01 '26	Option Exercise	1.70	80,000	136,000	105,076	Apr 03 09:00 AM
Garner Ebun	Chief Legal Officer	Apr 01 '26	Sale	16.40	80,000	1,312,000	25,076	Apr 03 09:00 AM
Ebun Garner	Officer	Apr 01 '26	Proposed Sale	16.40	80,000	1,312,355		Apr 01 02:19 PM
Erasca Foundation	Foundation	Mar 16 '26	Proposed Sale	14.02	8,333	116,855		Mar 16 02:38 PM
Morris Shannon	Chief Medical Officer	Mar 04 '26	Option Exercise	1.70	20,000	34,000	20,000	Mar 06 09:00 AM
Morris Shannon	Chief Medical Officer	Mar 04 '26	Sale	15.04	20,000	300,760	0	Mar 06 09:00 AM
Shannon Morris	Officer	Mar 04 '26	Proposed Sale	15.04	20,000	300,769		Mar 04 05:38 PM
Erasca Foundation	Foundation	Feb 17 '26	Proposed Sale	11.91	8,333	99,245		Feb 17 02:27 PM
Erasca Foundation	Foundation	Jan 15 '26	Proposed Sale	8.23	8,333	68,574		Jan 15 10:43 AM
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Option Exercise	1.70	120,000	204,000	145,076	Jan 08 09:20 PM
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Sale	5.59	120,000	670,812	25,076	Jan 08 09:20 PM
Ebun Garner	Officer	Jan 07 '26	Proposed Sale	5.59	120,000	670,809		Jan 07 03:58 PM
Erasca Foundation	Foundation	Dec 15 '25	Proposed Sale	3.65	8,333	30,439		Dec 15 08:11 PM
Erasca Foundation	Erasca Foundation	Nov 17 '25	Proposed Sale	2.60	8,333	21,626		Nov 17 04:27 PM

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Co-FounderDr. Jonathan E. Lim M.D.

CFO & Chief Business OfficerDr. David M. Chacko M.D.

Chairman of Research & DevelopmentDr. Michael D. Varney Ph.D.

Ph.D.Dr. Shannon R. Morris M.D.

Senior Vice President of AccountingMs. Alison Tjosvold Milhous

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS

Erasca Inc

Upgrade your Finviz experience